Advertisement
"Nastech continues to make significant progress in its peptide and proteintherapeutic programs utilizing our non-injectable drug delivery technology aswell as the development of RNAi therapeutics and now has a strong pipeline ofproducts in or preparing to initiate Phase II clinical trials," stated StevenC. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer ofNastech. "For this year's analyst and institutional investor day event,Nastech is pleased to have gathered leading experts in their respective fieldsto highlight three areas at the core of Nastech's drug development. Thisevent will also lend insight into Nastech's technologies and business, as wecontinue to execute upon a strategy that we believe has the potential todeliver important therapies to patients while creating significant value forour shareholders."
Advertisement
The invitation-only event will be webcast commencing at 12:30 p.m. EasternTime. To access the live webcast for this conference, please log on toNastech's website at http://www.nastech.com approximately 15 minutes prior tothe presentation in order to register and download any necessary software.
About Nastech
Nastech is a biopharmaceutical company developing innovative productsbased on proprietary molecular biology-based drug delivery technologies.Nastech and our collaboration partners are developing products for multipletherapeutic areas including osteoporosis, obesity, diabetes, autism,respiratory diseases and inflammatory conditions. Additional information aboutNastech is available at http://www.nastech.com.
Nastech Forward-Looking Statements
Statements made in this press release may be forward-looking statementswithin the meaning of Federal Securities laws that are subject to certainrisks and uncertainties and involve factors that may cause actual results todiffer materially from those projected or suggested. Factors that could causeactual results to differ materially from those in forward-looking statementsinclude, but are not limited to: (i) the ability of Nastech to obtainadditional funding; (ii) the ability of Nastech to attract and/or maintainmanufacturing, research, development and commercialization partners; (iii)Nastech's and/or a partner's ability to successfully complete product researchand development, including preclinical and clinical studies andcommercialization; (iv) Nastech's and/or a partner's ability to obtainrequired governmental approvals; and (v) Nastech's and/or a partner's abilityto develop and commercialize products that can compete favorably with those ofcompetitors. Additional factors that could cause actual results to differmaterially from those projected or suggested in any forward-looking statementsare contained in Nastech's most recent periodic reports on Form 10-K and Form10-Q that are filed with the Securities and Exchange Commission. Nastechassumes no obligation to update and supplement forward-looking statementsbecause of subsequent events.-- Robert S. Lindsay, M.B.Ch.B., Ph.D., F.R.C.P., Chief of Internal Medicine, Helen Hayes Hospital and Director of its Clinical Research Center, and Professor of Clinical Medicine, Columbia University, will provide an overview of osteoporosis and give expert insight on the use of Parathyroid Hormone (PTH1-34) as a therapy for this disease. --
